De Novo device
Neurolyser XR (NXR100)
Fusmobile, Inc. · High Intensity Focused Ultrasound System For Peripheral Neural Tissue Ablation (SGN, Class II) · First FDA decision Nov 14, 2025, newest Nov 14, 2025Chronic pain
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
De Novo pathway
Device trials
9
Naming "Neurolyser XR"
MAUDE reports
0
Brand "Neurolyser XR", since 2015
PubMed studies
0
Mentioning "Neurolyser XR"
AI summary across all sources
Written by Claude (Anthropic's AI) from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- Neurolyser XR (NXR100)New device typeDe Novo
DEN250015 · Decided Nov 14, 2025 · 203 days after receipt
Device type: High Intensity Focused Ultrasound System For Peripheral Neural Tissue Ablation (SGN) · Neurology & Neurosurgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Magnetic Resonance Image Guided High Intensity Focused Ultrasound (MRgFUS) for TremorProposed local determinationProposedDL37421National Government Services, Inc.Updated Sep 18, 2025
- Magnetic-Resonance-Guided Focused Ultrasound Surgery (MRgFUS) for Essential Tremor and Tremor Dominant Parkinson's DiseaseLocal determinationIn effectL37729Noridian Healthcare Solutions, LLCUpdated Sep 2, 2025
- Peripheral Venous UltrasoundLocal determinationIn effectL33693First Coast Service Options, Inc.Updated Dec 8, 2023
- Peripheral Venous UltrasoundLocal determinationIn effectL35451Novitas Solutions, Inc.Updated Dec 8, 2023
- Ultrasound, Soft Tissues of Head and NeckLocal determinationIn effectL34027First Coast Service Options, Inc.Updated Sep 18, 2019
Clinical trials
Device studies on ClinicalTrials.gov that name "Neurolyser XR", any status and sponsor, newest update first.
- Safety and Feasibility of the NeurolyserXR for Sacroiliac Joint PainActive, not recruiting
FUSMobile Inc.Not on our public-company list
NCT05396495 · 10 participants (planned) · Start Sep 24, 2024 · Primary completion May 1, 2027
Device: NeurolyserXR · For: Sacroiliitis
Sites: Giv‘atayim, Israel
- Study Designed to Assess the Efficacy and Safety of the Neurolyser XR After Marketing ApprovalNot yet recruiting
FUSMobile Inc.Not on our public-company list
NCT07926581 · 60 participants (planned) · Start Nov 12, 2026 · Primary completion Dec 31, 2029
Device: High Intensity Focused Ultrasound · For: Lumbar Zygapophyseal Pain; Low Back Pain; Facet Joint Pain; Low Back Pain
Sites: Alicante, Spain
- Use of the Neurolyser XR for the Treatment of Low Back Pain Related to SacroiliitisActive, not recruiting
FUSMobile Inc.Not on our public-company list
NCT06053255 · 10 participants (planned) · Start Sep 13, 2024 · Primary completion May 26, 2027
Device: High-intensity focused ultrasound for Sacroiliitis using the Neurolyser XR · For: Sacroiliitis
Sites: Charlottesville, Virginia
FUSMobile Inc.Not on our public-company list
NCT07178951 · 10 participants (planned) · Start Sep 9, 2026 · Primary completion Dec 31, 2026
Device: Neurotomy of the medial sensory articular branches · For: Osteoarthritis (OA) of the Knee; Knee Pain Arthritis; Chronic Knee Pain
Sites: North York, Canada
- Neurolyser XR for the Treatment of SacroiliitisNot yet recruiting
Federico II UniversityAcademic, hospital or other
NCT07647757 · 30 participants (planned) · Start Jul 2026 · Primary completion Jul 2027
Device: Patients treated with high intensity focused ultrasound · For: Sacroiliitis; Low Back Pain
Sites: Naples, Italy
- Double Arm Pivotal Study to Evaluate the Neurolyser XR for the Treatment of Chronic Low Back PainPivotal-lookingCompleted
FUSMobile Inc.Not on our public-company list
NCT05154448 · 90 participants · Start May 16, 2022 · Primary completion Apr 16, 2024
Device: Non-Invasive Thermal Ablation of the Medial Branch Nerves (Neurolyser XR) · For: Facet Syndrome of Lumbar Spine
Sites: Stamford, Connecticut; Jacksonville, Florida; Miami, Florida · 10 sites in all
FUSMobile Inc.Not on our public-company list
NCT04519541 · 10 participants · Start Feb 3, 2021 · Primary completion Sep 11, 2022
Device: Non-Invasive Thermal Ablation of the Medial Branch Nerves using the Neurolyser XR · For: Facet Syndrome of Lumbar Spine
Sites: Haifa, Israel
- Safety and Initial Feasibility of Using the Neurolyser XR Device for the Treatment of Axial Chronic Low Back PainStatus unknown
FUSMobile Inc.Not on our public-company list
NCT04129034 · 30 participants · Start Sep 24, 2019 · Primary completion Oct 26, 2022
Device: Neurolyser XR · For: Facet Syndrome of Lumbar Spine
Sites: Vancouver, Canada; Oakville, Canada; Toronto, Canada · 5 sites in all
FUSMobile Inc.Not on our public-company list
NCT03321344 · 10 participants · Start Dec 5, 2017 · Primary completion Feb 28, 2019
Device: Focused Ultrasound Thermal ablation · For: Facet Related Low Back Pain
Sites: Montreal, Canada
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Neurolyser XR", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code SGN
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Neurolyser XR"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.